ClinicalTrials.gg
RecruitingNCT05735145Updated Feb 21, 2023

Concurrent Chemoradiotherapy Combined With Adjuvant Chemotherapy Treated Advanced Cervical Cancer

A Phase 3 interventional study of paclitaxel combined with platinum in Uterine Cervical Neoplasms, Chemoradiotherapy and Adjuvant Chemotherapy, sponsored by Fourth Affiliated Hospital of Guangxi Medical University. Recruiting at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-02-21.

Sponsored by Fourth Affiliated Hospital of Guangxi Medical University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Jul 2022; still recruiting 4 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies testing paclitaxel in Uterine Cervical Neoplasms — 12 open to participants now, 13 under way, 8 of them phase 3. Paclitaxel · Uterine Cervical Neoplasms.

Planned enrollment
19th of 46
108 · median 65
Started
2022
with 3 others
Phase 3
16 of 47
7 open now
Primary completion
2025-06
later than 4 of 12 live
Registered
42nd of 47
by date

Among the 47 studies testing paclitaxel in Uterine Cervical Neoplasms, this one is the 19th largest by planned enrollment of the 46 interventional ones that give a count, is one of 4 that started in 2022, is one of 16 in phase 3, reaches primary completion later than 4 of the 12 other live ones, and was the 42nd registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

12 of the 47 studies testing paclitaxel in Uterine Cervical Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About paclitaxel

Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies testing paclitaxel in Uterine Cervical Neoplasms, or all of them as a file.
02

Study summary

This study carried out a prospective, randomized, controlled clinical study under the background of intensity-modulated radiation therapy and three-dimensional afterloading therapy. By comparing simultaneous intensity-modulated radiotherapy and chemotherapy combined with adjuvant chemotherapy and simultaneous intensity-modulated radiotherapy and chemotherapy alone, based on the 2018 FIGO staging The clinical efficacy of locally advanced cervical cancer further clarifies the role of adjuvant chemotherapy in locally advanced cervical cancer.

Read the detailed description

Concurrent chemoradiotherapy is the standard treatment for locally advanced cervical cancer, but there are still many patients with local recurrence or metastasis after treatment, and the 5-year survival rate is low. Concurrent chemoradiotherapy followed by adjuvant chemotherapy for locally advanced cervical cancer is still controversial in improving disease-free survival and overall survival, and previous studies were mostly based on traditional two-dimensional radiotherapy techniques, intensity-modulated radiotherapy and three-dimensional afterloading in dosimetry and radiotherapy. Compared with traditional radiotherapy, it has more advantages in terms of biological effects. In addition, after the adjustment of the new 2018 FIGO staging, it is possible to change the impact of the original treatment mode on overall survival. Therefore, more evidence-based medical evidence is needed to clarify the clinical value of adjuvant chemotherapy in the treatment of locally advanced cervical cancer. Therefore, this study carried out a prospective, randomized, controlled clinical study under the background of intensity-modulated radiation therapy and three-dimensional afterloading therapy. By comparing simultaneous intensity-modulated radiotherapy and chemotherapy combined with adjuvant chemotherapy and simultaneous intensity-modulated radiotherapy and chemotherapy alone, based on the 2018 FIGO staging The clinical efficacy of locally advanced cervical cancer further clarifies the role of adjuvant chemotherapy in locally advanced cervical cancer.

03

Conditions studied

  • Uterine Cervical Neoplasms
  • Chemoradiotherapy
  • Adjuvant Chemotherapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cervical cancer confirmed by histopathology incloud squamous cell carcinoma, adenocarcinoma and adenosquamous carcinoma
  • FIGO stage IB3, IIA2, IIB-IVA patients in 2018
  • Locally advanced cervical cancer patients received standard concurrent intensity-modulated chemoradiotherapy followed by three-dimensional afterloading treatment after diagnosis, and the effect reached CR after treatment
  • Aged 18-75 years
  • PS score 0-1
  • Serum >=100*10\^9/L, blood >= 100000/μL, absolute count of neutrophils>=1500/μL; 7.Serum creatinine \<=1.5 UNL or >= 60 ml/min; 8.Serum \<=1.5 UNL, (SGOT) and ALT (SGPT)\<= 1.5 UNL
  • Sign a formal to show that they understand that the study is in line with hospital and national policies .Estimated total survival > 6 months.

Exclusion criteria

Exclusion Criteria:

  • Locally advanced cervical cancer patients received standard concurrent intensity-modulated chemoradiotherapy followed by three-dimensional afterloading treatment after diagnosis, and the effect unreached CR after treatment
  • Patients who have received chemotherapy and surgery
  • Patients with cognitive impairment
  • Patients with any distant
  • Patients with any other within 5 years
  • Any other disease or condition is to chemoradiotherapy (e.g., active infection, 6 months after myocardial infarction, symptomatic heart disease, including unstable angina, congestive heart failure or uncontrolled arrhythmias, therapy, etc.); 5.Pregnant or lactating women, or fertile women who do not use
  • Severe bone marrow dysfunction
  • Patients with bleeding tendency
  • Drug abusers or alcohol addicts
  • Those who are known to have a third or fourth degree allergic reaction to any treatment in the study
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    concurrent chemoradiotherapy combined with adjuvant chemotherapy

    Adjuvant chemotherapy in patients with locally advanced cervical cancer who achieved CR after concurrent chemoradiotherapy

    Drug: paclitaxel combined with platinum

  • Other
    concurrent chemoradiotherapy

    Observation of patients with locally advanced cervical cancer who achieved CR after concurrent chemoradiotherapy

    Drug: paclitaxel combined with platinum

Interventions

06

What researchers measure

Primary outcomes

  1. PFS

    progression-free survival

    Time frame: Refers to the time from randomization to the first occurrence of disease progression or death from any cause,whichever came first, assessed up to 1000 months

Secondary outcomes

  1. OS

    Overall survival

    Time frame: Refers to the time from randomization to death from any cause, assessed up to 1000 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Jun 2025, 35 months after the start.

Of 53 non-industry phase 3 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 80 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 107. This study's planned 35 months is below that.

Counting every sponsor, half of 99 studies reached it within 55 months; a quarter within 24 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2022
First posted
Feb 21, 2023
StartActual
Jul 1, 2022
Primary completionEst.
Jun 30, 2025
CompletionEst.
Jun 30, 2027
Last update
Feb 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05735145
Lead sponsor
Fourth Affiliated Hospital of Guangxi Medical University
Responsible party
Sponsor
First posted
Feb 21, 2023
Start date
Jul 1, 2022
Primary completion
Jun 30, 2025 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Feb 21, 2023

Study contacts

Huang haixin
Contact
13507726193@163.com
13507726193
Feng chengjun
Contact
leymj@163.com
18877279562
Feng chengjun
principal investigator · The The Fourth Affiliated Hospital of Guangxi Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Paclitaxel · Platinum Compounds

Start the discussion